Dividends, FDA Approved Treatments, Clinical Data Presentations and Completed License Applications - Research Report on Medtronic, Auxilium, Alnylam, Infinity, and Halozyme Editor Note: For more information about this release, please scroll to bottom PR Newswire NEW YORK, December 11, 2013 NEW YORK, December 11, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Medtronic, Inc. (NYSE: MDT), Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), and Halozyme Therapeutics, Inc. (NASDAQ: HALO). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Medtronic, Inc. Research Report On December 5, 2013, Medtronic, Inc. (Medtronic) reported that its Board of Directors has approved a cash dividend in the amount of $0.28 per share on the Company's common stock, for Q3 FY 2014. The dividend is payable on January 24, 2014, to shareholders of record at the close of business on January 3, 2014. The Full Research Report on Medtronic, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://analystscorner.com/microwriter/link.php?s=DDD http://www.analystscorner.com/r/full_research_report/bc94_MDT -- Auxilium Pharmaceuticals Inc. Research Report On December 6, 2013, Auxilium Pharmaceuticals, Inc. (Auxilium) announced that the US Food and Drug Administration (FDA) has approved XIAFLEX, a biologic for the treatment of Peyronie's disease (PD). "In my practice, treating PD has been a challenge as, until now, we have had few options to offer our patients," said Martin K. Gelbard, M.D., clinical trial investigator and clinical faculty member of UCLA School of Medicine, Department of Urology. "I believe the FDA approval of XIAFLEX is a significant achievement and offers a new option for urologists: the first approved in-office treatment to be administered non-surgically that is proven safe and effective for this physically and psychologically devastating disorder." The Company further informed that it has created Auxilium Advantage™, providing a single point of contact for health care providers and patients for help accessing XIAFLEX. The Full Research Report on Auxilium Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://analystscorner.com/microwriter/link.php?s= http://www.analystscorner.com/r/full_research_report/86a4_AUXL -- Alnylam Pharmaceuticals, Inc. Research Report On December 8, 2013, Alnylam Pharmaceuticals, Inc. (Alnylam) announced the presentation of its new pre-clinical data with ALN-CC5, a subcutaneously administered RNAi therapeutic targeting complement component C5 for the treatment of complement-mediated diseases. According to Alnylam, the data demonstrate that subcutaneous administration of ALN-CC5 in non-human primates (NHPs) led to an up to 98% knockdown of serum C5 and an up to 94% inhibition of hemolytic activity. Akshay Vaishnaw, M.D., Ph.D., Executive Vice President and Chief Medical Officer of Alnylam said, "C5 is both a genetically and clinically validated target that exemplifies the potential of Alnylam's '5x15' product strategy for innovative new medicines. First, C5 is predominantly expressed in liver, where we have established robust clinical activity and tolerability for RNAi therapeutics." The Full Research Report on Alnylam Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://analystscorner.com/microwriter/link.php?s= http://www.analystscorner.com/r/full_research_report/5b29_ALNY -- Infinity Pharmaceuticals, Inc. Research Report On December 7, 2013, Infinity Pharmaceuticals, Inc. (Infinity) announced preclinical data showing the activity of IPI-145 in models of diffuse large B-cell lymphoma (DLBCL) and T-cell acute lymphoblastic leukemia (T-ALL), both of which are difficult-to-treat hematologic malignancies (blood cancers). Infinity informed that IPI-145 is its oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma. "The preclinical data reported today, as well as early clinical data in aggressive non-Hodgkin lymphoma, further underscore the potential of IPI-145 to treat a broad range of blood cancers," stated Julian Adams, Ph.D., President of R&D at Infinity. Adams added, "IPI-145 has already shown clinical activity in indolent non-Hodgkin lymphoma and chronic lymphocytic leukemia, and we are advancing IPI-145 in late-stage development in these two indications. The preclinical data reported today are expanding our understanding of the mechanism of action of IPI-145 and the roles of PI3K-delta and PI3K-gamma, which will help inform further clinical development." The Full Research Report on Infinity Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://analystscorner.com/microwriter/link.php?s= http://www.analystscorner.com/r/full_research_report/3862_INFI -- Halozyme Therapeutics, Inc. Research Report On December 2, 2013, Halozyme Therapeutics, Inc. (Halozyme) and Baxter International Inc. (Baxter) jointly reported that Baxter has completed submission of an amended biologics license application (BLA) to the US Food and Drug Administration (FDA) to re-initiate the review process for approval of HyQvia facilitated subcutaneous infusion for the treatment of adult patients with primary immunodeficiency (PI). Both the Companies submitted additional preclinical data that was requested from the FDA in 2012, and expect a six-month review period. "We believe that if approved, HyQvia may become a valuable option for patients with immune deficiency as it allows for the delivery of a full dose of immunoglobulin often in a single site every three to four weeks, in the comfort of a patient's home," said Ludwig Hantson, Ph.D., President of Baxter's BioScience business. "As a long-standing leader in the IG market, we are committed to continually developing new treatment options like HyQvia that have the potential to make a meaningful difference in the way patients are treated." The Full Research Report on Halozyme Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://analystscorner.com/microwriter/link.php?s= http://www.analystscorner.com/r/full_research_report/ea1b_HALO ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. SOURCE Analysts' Corner Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
Dividends, FDA Approved Treatments, Clinical Data Presentations and Completed License Applications - Research Report on
Press spacebar to pause and continue. Press esc to stop.